Session » Vasculitis Poster I: Large Vessel Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 781
A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 799
Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 798
Altered Phenotype of Platelets and Neutrophils Toward Neutrophil-Platelet Interaction in Circulation of Small and Large Vessel Vasuculitis
- 9:00AM-11:00AM
-
Abstract Number: 791
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
- 9:00AM-11:00AM
-
Abstract Number: 808
Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort
- 9:00AM-11:00AM
-
Abstract Number: 779
Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)
- 9:00AM-11:00AM
-
Abstract Number: 807
B Cells in Giant Cell Arteritis: a Novel Target for Treatment?
- 9:00AM-11:00AM
-
Abstract Number: 803
Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 795
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
- 9:00AM-11:00AM
-
Abstract Number: 814
Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
- 9:00AM-11:00AM
-
Abstract Number: 816
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
- 9:00AM-11:00AM
-
Abstract Number: 818
Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR
- 9:00AM-11:00AM
-
Abstract Number: 784
Damage and Predictors of Damage in Takayasu’s Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 777
Differences between Temporal Artery Biopsy-Positive and Biopsy-Negative Giant Cell Arteritis: A Comparative Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 821
Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 806
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
- 9:00AM-11:00AM
-
Abstract Number: 783
European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice
- 9:00AM-11:00AM
-
Abstract Number: 817
Extension of Affected Vascular Territories in Secondary Aortitis Is Associated to Different Clinical Subtypes?
- 9:00AM-11:00AM
-
Abstract Number: 792
Glucocorticoid Use and Adverse Events in Patients with Polymyalgia Rheumatica in a Contemporary Population-Based Cohort
- 9:00AM-11:00AM
-
Abstract Number: 815
Incidence in Large Vessel GCA in Northern Italy during a 11-Year Period
- 9:00AM-11:00AM
-
Abstract Number: 813
Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 824
Long Term Efficacy and Safety of Intravenous and Subcutaneous Biologics in Large Vessels Vasculitis: 21 Patients Belonging to a Single Italian Center from 2011 to 2017
- 9:00AM-11:00AM
-
Abstract Number: 785
Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 789
Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 788
Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 800
Measurement of Serum Cytokines during the Apparent Remission State of Takayasu Arteritis – What Do Cytokines Tell Us?
- 9:00AM-11:00AM
-
Abstract Number: 793
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
- 9:00AM-11:00AM
-
Abstract Number: 812
Mortality Risk and Cause-Specific Mortality in Polymyalgia Rheumatica: A Population-Based Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 794
Negative Temporal Artery Biopsies: Comparison between Biopsy-Negative GCA and Non-GCA Patients
- 9:00AM-11:00AM
-
Abstract Number: 801
PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?
- 9:00AM-11:00AM
-
Abstract Number: 790
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
- 9:00AM-11:00AM
-
Abstract Number: 796
Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
- 9:00AM-11:00AM
-
Abstract Number: 809
Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study
- 9:00AM-11:00AM
-
Abstract Number: 787
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
- 9:00AM-11:00AM
-
Abstract Number: 820
Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 825
Radiological Disease Activity Is the Major Determinant for Physicians While Deciding Active Disease in Takayasu Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 819
Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 778
Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations
- 9:00AM-11:00AM
-
Abstract Number: 823
Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
- 9:00AM-11:00AM
-
Abstract Number: 810
Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data
- 9:00AM-11:00AM
-
Abstract Number: 802
Sensorineural Hearing Loss in Takayasu’s Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 805
Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
- 9:00AM-11:00AM
-
Abstract Number: 782
Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
- 9:00AM-11:00AM
-
Abstract Number: 780
Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice
- 9:00AM-11:00AM
-
Abstract Number: 786
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
- 9:00AM-11:00AM
-
Abstract Number: 797
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
- 9:00AM-11:00AM
-
Abstract Number: 804
The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
- 9:00AM-11:00AM
-
Abstract Number: 822
The Incidence Rate of Deep Vein Thrombosis and/or Pulmonary Embolism in Patients with Giant Cell Arteritis – Single Center Observational Study